## Edgar Filing: HEMACARE CORP /CA/ - Form 8-K

HEMACARE CORP /CA/ Form 8-K March 25, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 25, 2004

HEMACARE CORPORATION

(Exact name of registrant as specified in its charter)

CALIFORNIA 000-15223 95-3280412 (State or other (Commission File No.) (I.R.S. employer jurisdiction of organization or incorporation)

21101 Oxnard Street
Woodland Hills, CA 91367
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (818) 226-1968

Item 7. Financial Statements and Exhibits.

#### (c) Exhibits

Exhibit Number	Description
99.1	Press Release issued by HemaCare Corporation, dated March 25, 2004
99.2	Transcript of the presentations given by Judi Irving, CEO, and Robert S. Chilton, CFO, at a conference call conducted by HemaCare Corporation on March 25, 2004

Item 12 Results of Operations and Financial COndition

On March 25, 2004, HemaCare Corporation issued a press release announcing the financial results for the year ended December 31, 2003. A copy is attached as Exhibit 99.1 to this report and is incorporated herein by this reference.

Additionally, on March 25, 2004, HemaCare Corporation held an investor conference call discussing the financial results for the year ended December 31, 2003. A transcript of the presentations given by Judi Irving, CEO, and Robert S. Chilton, CFO, in the call is attached to this report as Exhibit 99.2 and is incorporated herein by this reference.

The information in this Current Report on Form 8-K, including the exhibits, will not be treated as "filed" for the purposes of

# Edgar Filing: HEMACARE CORP /CA/ - Form 8-K

Section 18 of the Securities and Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section. This information will not be incorporated by reference into a filing under the Securities Act of 1933, or into another filing under the Exchange Act, unless that filing expressly refers to specific information in this report.

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 25, 2004 HEMACARE CORPORATION

/s/ Robert S. Chilton

Robert S. Chilton Chief Financial Officer

### EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release issued by HemaCare, Corporation dated March 25, 2004
99.2	Transcript of the presentations given by Judi Irving, CEO, and Robert S. Chilton, CFO, at a conference call conducted by HemaCare Corporation on March 25, 2004